A unique siRNA reagent for neuronal, immune, primary, stem, and other difficult-to-transfect cells
To achieve robust silencing of a target gene with siRNA, the first critical step is efficient delivery of siRNA into the cells of interest. However, many neuronal, immunological, primary, and stem cells are refractory to traditional lipid or electroporation methods, so are at a disadvantage for using standard siRNA reagents. Luckily, we have a unique solution for these issues: Dharmacon Accell siRNA.
Accell siRNA combines our expertise in algorithmic siRNA design with a patented chemical modification pattern from our advanced synthesis chemistry.
The novel passive-entry mechanism of Accell has been demonstrated to be successful in numerous difficult-to-transfect cell types without any need for transfection reagents, lentiviral vectors, or electroporation/nucleofection instruments:
Another advantage to the Accell passive delivery strategy is that reapplication of siRNA can be used without the cytotoxic effects related to lentiviral or lipid-based products. This allows one to achieve long-term gene knockdown for studies that may need extended duration of silencing (up to 30 days tested in Dharmacon labs). Such approaches can be beneficial to the researcher who needs to accurately assess the contribution of a protein with a longer half-life than is impacted with traditional siRNA methods (4-6 days). A published example of this approach in rat primary cortical neurons achieved robust target silencing after 10 days with Accell siRNA treatments at 3 day intervals. 5
Interested in getting started with Accell? Check out our list of published references or in vivo reading list to see if Accell has been used with your cell system already. If not, Accell Control Kits are an economical way to optimize serum amount (<3% recommended) and delivery conditions.
Selected peer-reviewed publications have cited their successful use in a variety of experimental systems.
siRNA application in difficult-to-transfect cell types, like primary or suspension cells, is technically challenging. Novel, chemically-modified siRNAs offer a solution to this problem, as these siRNAs enter into difficult-to-transfect cell types without the need of a delivery reagent.
Poster describing use of Accell siRNA for high content screening in IMR-32 neuroblastoma cells and primary rat cortical neurons.
A large number of patients worldwide suffer from neuronal disorders such as Alzheimer’s, Parkinson’s, and Huntington’s diseases.